Peptide conjugated particles

• US 10,188,711 B2
• Filed: 11/02/2016
• Issued: 01/29/2019
• Est. Priority Date: 08/13/2013
• Status: Active Grant

• Current Assignee: Northwestern University
• Original Assignee: Northwestern University
• Inventors: Shea, Lonnie D., Miller, Stephen D., Yap, Jonathan Woon Teck, Getts, Daniel R., McCarthy, Derrick
• Primary Examiner(s): Navarro, Albert M
• Application Number:
  US15/341,935
• Publication Number:
  US 20170258880A1
• Time in Patent Office: 818 Days
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/577 tolerising response
• CPC Class Codes: A61K 2039/622 non-covalent binding
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0008 Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• CPC Class Codes: A61K 47/58 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: A61K 47/6937 the polymer being PLGA, PLA or polyglycolic acid
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61K 9/5153 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 5/06 : of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 : Antianaemics

Abstract

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

Claims

1. A composition comprising surface functionalized biodegradable particles comprising encapsulated allergen or one or more antigenic epitopes thereof, wherein the particle has a negative zeta potential of about −

100 mV to about −

30 mV.

2. The composition of claim 1, wherein the allergen is a food allergen.

3. The composition of claim 2, wherein the food allergen is a peanut allergen.

4. The composition of claim 1, wherein the allergen is an inhaled substance.

5. The composition of claim 1 wherein the allergen is selected from the group consisting of Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1-Caein Milk allergen, Api g 1 celery allergen, Bere1 Brazil nut allergen, B-Lactoglobulin Milk allergen, Bovine serum albumin, Cor a 1.04 Hazelnut allergen, Ovalbumin Egg allergen, peanut proteins, bee venom proteins, ragweed pollen proteins, pet dander proteins, house dust mite allergen Der p 1, and/or an antigenic epitope thereof.

6. The composition of claim 1, wherein the particles comprise poly(lactide-co-glycolide)(PLG).

7. The composition of claim 6, wherein the particles comprise PLG with a copolymer ratio of about 50:

50 of polylactic acid;

polyglycolic acid.

8. The composition of claim 1, wherein the surface functionalization is carboxylation.

9. The composition of claim 8, wherein the carboxylation is achieved by using poly(ethylene-maleic anhydride) (PEMA).

10. The composition of claim 1, wherein the particles have a zeta potential of about −

80 mV to about −

30 mV.

11. The composition of claim 1, wherein the particle has a diameter of between about 200 nm to about 2000 nm.

24. A method of treating an allergic disease or condition in a subject in need thereof comprising administering a pharmaceutical composition comprising the surface functionalized particles of claim 1.

25. The method of claim 24 wherein the allergic disease or condition is selected from the group consisting of food allergy, an environmental allergy, lung allergy, a skin allergy and asthma.

29. The composition of claim 1 wherein the particles have a copolymer ratio of about 80:

20, 90;

10 or 100;

0 of polylactic acid;

polyglycolic acid or polyglycolic acid;

polylactic acid.

12. A composition comprising surface functionalized biodegradable PLG particles comprising encapsulated allergen or one or more antigenic epitopes thereof wherein said PLG particles have a copolymer ratio of about 50:

50 poly(lactide-co-glycolide), a diameter of about 200 nm to about 2000 nm and a zeta potential of about −

30 my to about −

80 mV.

13. A lyophilized composition comprising surface functionalized biodegradable particles comprising encapsulated allergen or one or more antigenic epitopes thereof, wherein the particle has a negative zeta potential of about −

100 mV to about −

30 mV.

14. The lyophilized composition of claim 13, wherein the allergen is a food allergen.

15. The lyophilized composition of claim 13, wherein the allergen is an inhaled substance.

16. The lyophilized composition of claim 13 wherein the allergen is selected from the group consisting of Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1-Caein Milk allergen, Apig1 celery allergen, Bere1 Brazil nut allergen, B-Lactoglobulin Milk allergen, Bovine serum albumin, Cor a 1.04 Hazelnut allergen, Ovalbumin Egg allergen, peanut proteins, bee venom proteins, ragweed pollen proteins, pet dander proteins, house dust mite allergen Der p 1 and/or an antigenic epitope thereof.

17. The lyophilized composition of claim 13, wherein the particles comprise poly(lactide-co-glycolide) (PLG).

18. The lyophilized composition of claim 17, wherein the particles comprise PLG with a copolymer ratio of about 50:

50 of polylactic acid;

polyglycolic acid.

19. The lyophilized composition of claim 13, wherein the surface functionalization is carboxylation.

20. The lyophilized composition of claim 19 wherein the carboxylation is achieved by using poly(ethylene-maleic anhydride) (PEMA).

21. The lyophilized composition of claim 13, wherein the particles have a zeta potential of about −

80 mV to about −

30 mV.

22. The lyophilized composition of claim 13, wherein the particle has a diameter of between about 200 nm to about 2000 nm.

26. A method of treating an allergic disease or condition in a subject in need thereof comprising reconstituting the lyophilized particles of claim 13 to obtain a reconstituted pharmaceutical composition comprising surface functionalized particles and administering the reconstituted pharmaceutical composition to said subject thereby treating an allergic disease or condition.

27. The method of claim 26 wherein the allergic disease or condition is selected from the group consisting of food allergy, an environmental allergy, lung allergy, a skin allergy and asthma.

30. The lyophilized composition of claim 13 wherein the particles have a copolymer ratio of about 80:

20, 90;

10 or 100;

0 of polylactic acid;

polyglycolic acid or polyglycolic acid;

polylactic acid.

23. A lyophilized composition comprising surface functionalized biodegradable PLG particles comprising encapsulated allergen or one or more antigenic epitopes thereof wherein said PLG particles have a copolymer ratio of about 50:

50 poly(lactide-co-glycolide), a diameter of about 200 nm to about 2000 nm and a zeta potential of about −

30 my to about −

80 mv.

28. A method of treating an allergic disease or condition in a subject in need thereof comprising reconstituting the lyophilized particles of claim 23 to obtain a reconstituted pharmaceutical composition comprising surface functionalized particles and administering the reconstituted pharmaceutical composition to said subject thereby treating an allergic disease or condition.